v3.26.1
Note 1 - Business and Organization (Details Textual)
3 Months Ended
Mar. 31, 2026
USD ($)
Mar. 31, 2025
USD ($)
Dec. 31, 2025
USD ($)
Sep. 30, 2017
Number of Wholly-Owned Subsidiaries 5      
Revenue from Contract with Customer, Including Assessed Tax $ 1,115,000 $ 3,269,000    
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest (3,405,000) (1,921,000)    
Cash Provided by (Used in) Operating Activity, Discontinued Operation (2,917,000)      
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation 3,190,000 $ 866,000    
Assets, Current 5,445,000   $ 5,114,000  
Cash and Cash Equivalent 4,122,000   3,883,000  
Liabilities, Current 4,932,000   $ 5,063,000  
Working Capital (Deficit) $ 513,000      
Clyra Medical Technologies [Member]        
Subsidiary, Ownership Percentage, Parent 48.00%      
BioLargo Engineering, Science & Technologies, LLC [Member]        
Subsidiary, Ownership Percentage, Parent 70.00%     100.00%
BioLargo Energy Technologies, Inc (BETI) [Member]        
Subsidiary, Ownership Percentage, Parent 93.00%